Rokit Healthcare, a leading company specializing in artificial intelligence (AI) powered hyper-personalized long-term regeneration platforms, announced on Wednesday that it has secured certification for its AI kidney disease prediction solution, AI Kidney, paving the way for its entry into the U.S. market. The company has also signed a commercialization licensing agreement, with the solution set to officially launch in the U.S. next month.
A standout feature of this agreement is the impressive 18% royalty rate. Each user will generate a diagnostic royalty of approximately 50,000 KRW (about 34 USD).
Looking ahead, both companies plan to leverage their strategic partnership to expand their reach beyond the U.S., targeting 700 million chronic kidney disease patients worldwide, including those in South Korea, using the U.S.-certified AI kidney function prediction platform.
AI Kidney represents a paradigm shift in medical technology, moving beyond simple diagnosis to usher in the era of AI predictive medicine. The solution offers unparalleled patient convenience, requiring just a single drop of blood for testing. Its sophisticated AI algorithms provide highly accurate predictions of kidney function trends and estimated glomerular filtration rates over a five-year period.
Armed with these five-year kidney health projections, patients can take proactive steps to manage their individual lifestyle factors, including diet, hypertension, and obesity. This personalized approach could potentially prevent kidney function decline or eliminate the need for dialysis.
Rokit Healthcare plans to integrate the extensive medical data gathered through this solution with its flagship AI Kidney Regeneration Platform.
The company aims to unveil a comprehensive Full-Stack Kidney Management Model by next year. This innovative system will seamlessly connect high-risk patients, identified through AI predictive data, with cutting-edge regenerative treatment solutions.
A spokesperson for Rokit Healthcare stated that this licensing agreement validates the AI technology as a global standard and true game-changer in the field. They added that they’re poised to use the U.S. market as a launchpad to revolutionize kidney disease management worldwide, shifting the focus from reactive treatment to proactive prediction and prevention.